📄 What This Document Is

This is a formal update (an "SC TO-T/A" filing) about a tender offer—a type of direct buyout offer. Gilead Sciences is trying to buy all the shares of a smaller company called Arcellx. This specific filing announces that Gilead is extending the deadline for Arcellx shareholders to accept its offer.

👉 In simple terms: Gilead is saying, "We're still buying, and we're giving you more time to decide."

🏢 The Companies Involved

The Buyer: Gilead Sciences (GILD) is a giant biopharmaceutical company. Think of it as a veteran drug developer focused on serious illnesses like HIV, hepatitis, and cancer. They have a massive global operation.
The Target: Arcellx (ACLX) is a smaller, clinical-stage biotech company. Their key asset is a promising cancer treatment called anitocabtagene autoleucel (anito-cel), which is a type of cell therapy.

👉 Why it matters: This deal is about a big, established drug company (Gilead) buying a smaller company with a potentially blockbuster cancer drug to boost its future pipeline.

💰 The Deal Terms: Price & Payout

The offer has two potential cash payments for each Arcellx share:

Upfront Cash: $115.00 per share, paid immediately upon closing.
Contingent Value Right (CVR): An additional $5.00 per share, but only if a future sales target is met.

The CVR is like a "kicker" or a bonus. It pays out only if worldwide sales of the anito-cel drug exceed $6.0 billion by the end of 2029. If that happens, Arcellx shareholders get that extra $5 in 2030.

📅 Key Date Change: The Extended Deadline

This is the core news of the filing:

Old Expiration: April 2, 2026, at 11:59 p.m. ET.
New Expiration: April 24, 2026, at 5:00 p.m. ET.

The deal is still expected to close in the second quarter of 2026. The extension suggests Gilead needs more time to get enough shareholders on board or to finalize regulatory approvals.

📊 Current Status: Who's Tendered So Far?

The filing reveals a crucial number: as of March 31, 2026, only about 4.39 million Arcellx shares (about 7.5% of the total) have been formally tendered into the offer.

👉 Why it matters: This is a very low percentage. For the deal to close, Gilead needs shareholders tendering a majority of all outstanding shares. The extension is clearly necessary to reach that threshold.

⚖️ What's Next & Conditions to Close

The deal isn't guaranteed. It must clear several hurdles:

Shareholder Tender: Must get enough shares to meet the "majority" condition.
Regulatory Approval: Standard government clearances (likely antitrust).
Other Customary Conditions: Standard legal and financial deal clauses.

If these aren't met by the new deadline, the offer could be withdrawn or extended again.

🧠 The Analogy

Imagine a big bookstore (Gilead) wants to buy a small, popular local publisher (Arcellx) for its bestselling manuscript (anito-cel). The bookstore offers $115 cash per copy of the publisher's stock, plus a $5 "royalty certificate" only if the manuscript becomes a mega-bestseller (selling over $6B). The sale was ending this week, but since only 7.5% of stock owners have said "yes," the bookstore extends the deadline by three weeks to convince more people to sell.

📇 Key Contacts & People

For Gilead Sciences (the buyer):

Media: Ashleigh Koss, [email protected]
Investors: Jacquie Ross, [email protected]
Information Agent (for offer questions): Innisfree M&A Incorporated, toll-free (877) 800-5182

Documents are available from:

Gilead Sciences, Inc. 333 Lakeside Drive, Foster City, CA 94404, attention: Investor Relations. Phone: 1-800-GILEAD-5 or 1-650-574-3000.
Arcellx's website: https://ir.arcellx.com/financials/sec-filings/default.aspx
SEC website: www.sec.gov

🧩 Final Takeaway

Gilead is extending its $115-per-share cash offer (plus a potential $5 future bonus) for Arcellx until April 24, 2026, because only 7.5% of shareholders have tendered their shares so far. The extension is a critical move to secure the majority needed to complete the acquisition in Q2 2026.

Arcellx, Inc. — SC TO-T/A Filing